McNeil Products Ltd

Foundation Park, Roxborough Way, Maidenhead, Berks, SL6 3UG
Medical Information Direct Line: 01344 864042
Medical Information e-mail: medinfo@its.jnj.com


Summary of Product Characteristics last updated on the eMC: 20/03/2009
SPC Anusol Plus HC Ointment


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

ANUSOL PLUS HC OINTMENT


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 100 g of ointment contains the following active ingredients:-

Hydrocortisone acetate 0.25 g

Benzyl benzoate 1.25 g

Bismuth subgallate 2.25 g

Bismuth oxide 0.875 g

Balsam peru 1.875 g

Zinc oxide 10.75 g

For excipients, see 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Ointment.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Symptomatic treatment of internal and external haemorrhoids and pruritus ani.


Go to top of the page
4.2 Posology and method of administration

Topical administration.

ADULTS (over 18 years)

To be applied sparingly to the affected area at night, in the morning and after each evacuation up to a maximum of 4 applications a day. Thoroughly cleanse the affected area, dry and apply ointment on a gauze dressing. For internal conditions use rectal nozzle provided. Remove the nozzle cap. Clean the nozzle after each use. Use for a maximum period of one week.

ELDERLY (over 65 years)

As for adults

CHILDREN (under 18 years)

Not recommended.


Go to top of the page
4.3 Contraindications

Tubercular, fungal and most viral lesions including herpes simplex, vaccinia and varicella. History of sensitivity to any of the constituents.


Go to top of the page
4.4 Special warnings and precautions for use

As with all products containing topical steroids, the possibility of systemic absorption should be borne in mind.

Prolonged or excessive use may produce systemic corticosteroid effects and use for periods longer than seven days is not recommended.

The product should be discontinued and the patient advised to consult a medical practitioner if symptoms do not improve or worsen or if rectal bleeding occurs.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Concurrent use with other corticosteroid preparations, either topically or orally may increase the likelihood of systemic effects.


Go to top of the page
4.6 Pregnancy and lactation

There is inadequate evidence of safety in human pregnancy and there may be a very small risk of cleft palate and intrauterine growth retardation as well as suppression of the neonatal hypothalamic-pituitary-adrenal axis. There is evidence of harmful effects in animals. To be used in pregnancy only when there is no safer alternative and when the disease itself carries risks for the mother or child.

No special precautions required for use during lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

No effects have been reported on ability to drive or use machinery.


Go to top of the page
4.8 Undesirable effects

Rarely, sensitivity reactions may occur. Patients may occasionally experience transient burning on application, especially if the anoderm is not intact.


Go to top of the page
4.9 Overdose

If swallowed, fever, nausea, vomiting, stomach cramps and diarrhoea may develop 3-12 hours after ingestion.

Hydrocortisone normally does not produce toxic effects in an acute single overdose.

Treatment of a large acute overdose should include gastric lavage, purgation with magnesium sulphate and complete bed rest. If necessary oxygen and general supportive measures should be given. Methaemoglobinaemia should be treated by intravenous methylthioninium chloride.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

ANUSOL PLUS HC provides antiseptic, astringent, emollient and decongestant properties. In addition hydrocortisone exerts anti-inflammatory actions.

Bismuth oxide, zinc oxide, and bismuth subgallate exert a protective action on mucous membranes and raw surfaces. They are mildly astringent and are reported to have antiseptic properties.

Balsam Peru has protective properties and a very mild antiseptic action by virtue of its contents of cinnamic and benzoic acids. It is believed to promote the growth of epithelial cells.

Benzyl benzoate is used as a solubilizing agent and has mild antiseptic and preservative properties.

Hydrocortisone acetate has the general properties of hydrocortisone and this anti-inflammatory action is of primary interest of this product.


Go to top of the page
5.2 Pharmacokinetic properties

Systemic absorption of hydrocortisone acetate from the rectum may occur but estimates of the extent of absorption have been variable and have always been less than 30%. Following absorption it is metabolised in the liver and most body tissues before being excreted in the urine. Biological half life is approximately 100 minutes and it is 90% bound to plasma protein.

The other active ingredients in Anusol Plus HC Ointment exert their therapeutic effect without being absorbed into the systemic circulation. These are supported by evidence from various studies and reviews.


Go to top of the page
5.3 Preclinical safety data

The active ingredients of Anusol are well known constituents of medicinal products and their safety profile is well documented.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Kaolin light

Magnesium stearate

Castor oil

Cocoa butter

Lanolin anhydrous

Petroleum jelly white

Calcium hydrogen phosphate


Go to top of the page
6.2 Incompatibilities

No incompatibilities have been reported.


Go to top of the page
6.3 Shelf life

3 years.


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C


Go to top of the page
6.5 Nature and contents of container

Externally printed aluminium tube with wadded plastic cap, containing 15 g of ointment. A plastic nozzle with cap is also provided for internal application.


Go to top of the page
6.6 Special precautions for disposal and other handling

No Special Requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

McNeil Products Limited

Foundation Park

Roxborough Way

Maidenhead

Berkshire

SL6 3UG

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 15513/0039


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

9 March 2009


Go to top of the page
10. DATE OF REVISION OF THE TEXT

9 March 2009



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/7046/SPC/